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Background. Distinguishing between benign and malignant peripheral nerve sheath tumors (MPNSTs) in neurofibromatosis 1
(NF1) patients prior to excision can be challenging. How can MPNST be most accurately diagnosed using clinical symptoms,
magnetic resonance imaging (MRI) findings (tumor size, depth, and necrosis), positron emission tomography (PET) measures
(SUVpeak, SUVmax, SUVmax tumor/SUVmean liver, and qualitative scale), and combinations of the above?Methods. All NF1 patients
who underwent PET imaging at our institution (January 1, 2007–December 31, 2016) were included. Medical records were
reviewed for clinical findings; MR images and PETimages were interpreted by two fellowship-trainedmusculoskeletal and nuclear
medicine radiologists, respectively. Receiver operating characteristic (ROC) curves were created for each PETmeasurement; the
area under the curve (AUC) and thresholds for diagnosing malignancy were calculated. Logistic regression determined significant
predictors of malignancy. Results. Our population of 41 patients contained 34 benign and 36 malignant tumors. Clinical findings
did not reliably predict MPNST. Tumor depth below fascia was highly sensitive; larger tumors were more likely to be malignant
but without a useful cutoff for diagnosis. Necrosis on MRI was highly accurate and was the only significant variable in the
regression model. PETmeasures were highly accurate, with AUCs comparable and cutoff points consistent with prior studies. A
diagnostic algorithm was created using MRI and PET findings. Conclusions. MRI and PET were more effective at diagnosing
MPNST than clinical features. We created an algorithm for preoperative evaluation of peripheral nerve sheath tumors in NF1
patients, for which additional validation will be indicated.
1. Introduction
Neurofibromatosis type 1 (NF1) is one of the most common
autosomal-dominant diseases worldwide [1–8]. It has an in-
cidence of 1/2,500 to 1/3,500 individuals [1–5, 8, 9] and is caused
by mutations of the NF1 gene located on chromosome 17q11.2.
Clinically, the disease is characterized by multiple plexiform
neurofibromas that are usually benign; however, they have the
potential for malignant transformation, with a lifetime risk of
8–12% [1–5, 8]. Malignant peripheral nerve sheath tumors
(MPNSTs) are the leading cause of mortality in NF1, reducing
average life expectancy by 10–15 years [2, 6, 10, 11].
Differentiating between benign and malignant PNSTs
can be challenging, especially in individuals with multiple
neurofibromas. Traditionally, this has been attempted based
on imaging characteristics and symptoms, which may in-
clude pain, increasing size of a mass, and new neurological
deficit [5]. However, there is significant overlap in the ap-
pearance as well as clinical manifestations of benign and
malignant tumors [5, 12].
Several magnetic resonance imaging (MRI) features can
be useful in distinguishing MPNSTs from neurofibromas.
&ese include largest dimension of the mass, heterogeneity
indicating necrosis, peripheral enhancement pattern,
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perilesional edema-like zone, intratumoral cystic lesion, and
irregular margins [12, 13]. Of these features, tumor size and
necrosis are the best supported predictors for diagnosing
MPNST [12, 14–17] (Figure 1(a)).
Multiple efforts have been made to accurately diagnose
malignant transformation using metabolic imaging with
positron emission tomography/computed tomography
(PET/CT) and [18F]fluorodeoxyglucose (FDG) (Figure 1(b)).
Several authors have studied both semiquantitative and
qualitative methods of evaluating lesions with overall good
success [8, 18, 19]. Parameters for semiquantitative analysis
include but are not limited to mean standardized uptake
value (SUVmean), maximum SUV (SUVmax), maximum SUV
corrected for lean body mass (SULmax), and various ratios
comparing tumor FDG avidity to that of other tissues, such
as the liver, muscle, and fat. Among the most common of
these ratios is SUVmax tumor/SUVmean liver, also referred to as
the tumor-to-liver ratio (TLR). Semiquantitative methods
for diagnosing MPNST, such as mean SUVmax, have sen-
sitivities of 94%–100% and specificities of 76%–94% [18].
Similarly, qualitative methods, such as visual descriptions of
hypermetabolic lesions, have yielded sensitivities of 91%–
100% and specificities of 67%–95% [18, 20, 21].
In spite of this research, to our knowledge, a noninvasive
gold standard algorithm for diagnosing MPNST has not
been established, nor have imaging modalities been evalu-
ated in combination with clinical features. &e aim of our
retrospective study was to develop a strategy for dis-
tinguishing benign from malignant PNSTusing noninvasive
observations and tests, specifically clinical symptoms, MRI
features (size, depth, and necrosis), PETmeasures (SUVpeak,
SUVmax, SUVmax tumor/SUVmean liver, and qualitative scale),
and combinations of the above.
2. Materials and Methods
2.1. Patient Population and Data Collection. Following IRB
approval, all patients with a diagnosis of NF1 who were
treated at our institution between 1 January 2007 and 31
December 2016 were identified by searching the medical
oncology, nuclear medicine, and surgical databases at our
institution. Our study included all patients who underwent
FDG-PET/CT to evaluate for potential malignant trans-
formation of a PNST with available imaging and confirmed
histopathology. Electronic medical records were reviewed for
demographic information (patient age at time of surgery,
gender, and tumor location) as well as potential predictors for
malignancy. &ese included preoperative MRI features (tu-
mor size, tumor depth relative to the fascia, and necrosis) [22],
PET imaging measures (SUVmax, SUVpeak, and SUVmax tumor/
SUVmean liver), and clinical findings (pain, enlargement, and
nerve symptoms). Histopathology results from biopsy or
surgery obtained through chart review were used as the gold
standard for diagnosing benign versus malignant PNST.
2.2. MRI Analysis. MR images were assessed by two
fellowship-trained musculoskeletal radiologists blinded to
diagnoses. Tumor size was measured as the largest diameter
on T1 sequences and analyzed as both a continuous and
categorical variable, the latter using 5 cm as a cutoff based on
the AJCC staging system. Tumor depth was analyzed as a
categorical variable, either superficial or deep to the fascia.
Necrosis was defined as nonenhancement on T1 fat-
saturated postcontrast images, often with increased T2
signal intensity, and recorded in quartiles (0%, <25%, 25–
49%, 50–74%, and ≥75% necrosis).
2.3. FDG-PET/CT Protocol. Patients were imaged according
to our institution’s standard protocol for FDG-PET/CT,
which has previously been described [22]. In brief, pa-
tients fasted for at least 4 hours prior to FDG injection.
Blood glucose levels were required to be ≤200mg/dL prior to
FDG administration. Patients were injected with approxi-
mately 10–15mCi (370–555MBq) of FDG. &e PET/CT
acquisition was started approximately 60 minutes after
FDG injection. Patients were scanned from the base of the
skull to the upper-thigh with extension to extremities based
on the location of the lesion of the interest. Noncontrast CT
images were obtained first for attenuation correction and for
fusion with the PET images for lesion localization. PET
images were acquired at typically 6–8 bed positions, with an
acquisition time of 2–5 minutes per bed position.
2.4. Semiquantitative Analysis. SUVs were measured using
the commercial software Hermes (Hermes Medical Solu-
tions, Sweden) by placing a volume of interest (VOI) with a
diameter of 1.5 cm over the most intense region of the lesion
on the axial PET/CT images. For SUVmax, the highest SUV
and for SUVpeak, the average of the highest SUV within the
VOIs were measured and recorded. When necessary, the
diameter of the sphere was adjusted to accommodate for
lesion size. Mean liver SUV (average SUV within the VOIs)
was measured using the same 1.5 cm diameter sphere placed
over the right lobe of the liver. TLR was calculated using
SUVmax of the tumor over SUVmean of the liver.
2.5. Qualitative Analysis. FDG-PET/CT images were eval-
uated by one nuclear medicine physician and one nuclear
medicine fellow who had completed a diagnostic radiology
residency. Sites of abnormal metabolic activity were scored
on a 5-point scale based on the following criteria: score of
1� uptake similar to background, score of 2� uptake greater
than background but less than mediastinal blood pool
(MBP), score of 3� uptake>MBP but less than or equal to
liver, score of 4 uptake> liver, and score of 5� uptake
markedly> than liver (greater than 2-3 times).
2.6. Statistical Analysis. Tumor necrosis was analyzed as a
categorical variable, once with any necrosis considered a
positive finding and once with necrosis >25% considered a
positive finding. For each PET measurement, receiver op-
erating characteristic curves (ROC) were created, and the
area under the curve (AUC) was calculated, along with cutoff
points for diagnosing malignancy that optimized sensitivity
and specificity. When these were conflicting, sensitivity was
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prioritized in order to minimize false negative results in the
context of evaluating for malignancy. &ese cutoff points
and their sensitivity/specificity in our dataset were compared
to cutoff points previously reported in the literature. &e
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated for each
tumor characteristic, imaging measure, and clinical finding,
and relevant combinations of these variables. Logistic re-
gression was used to evaluate variables for predicting ma-
lignancy in combination. Superficial tumors were not
included in the model because no malignancies were ob-
served within this group. Potential predictors (tumor size,
necrosis, PET parameters, and clinical findings) were se-
lected for entry into the model based on the results of the
accuracy analysis above.
2.7. Diagnostic Algorithm. Our aggregate results were used
to create an algorithm for suggested evaluation of PNST in
NF1 patients. In order to develop a clinically relevant
workup strategy, tumors were first differentiated by tumor
features that can be determined by history and physical
examination, then by noninvasive imaging studies, and fi-
nally by biopsy. For each branch point, we calculated the
NPV and PPV to inform clinicians about the likelihood of
malignancy given the available information. Lastly, we used
the PPV from the noninvasive workup to offer recom-
mendations for management following biopsy, taking pre-
test probability into account.
3. Results
Our population of 41 patients contained 34 benign and 36
malignant tumors.&emean patient age was 30 years old for
the overall population (range 9–62). Within the 41 patients,
there was a predominance of tumors in females (41) com-
pared to males (29). &e majority of tumors were deep and
axially located, and the mean diameter was 6.5 cm (range
1.5–20.0 cm). Mean SUVmax, SUVpeak, and TLR were 7.9
(standard deviation (SD)± 5.4), 6.4 (SD± 4.3), and 4.0
(SD± 2.6), respectively. Necrosis was evident on MRI in 19
cases (51.4%). Most patients reported pain and enlargement
of tumors but not associated nerve symptoms. Additional
descriptive statistics including demographic information
and potential predictors of malignancy are summarized in
Table 1.
3.1. Clinical Findings. Clinical findings were available in 41
patients for 60 of the 70 tumors. Among patient symptoms,
we found that pain and enlargement were more sensitive
(sensitivity 85.2% and 85.2%; specificity 28.1% and 25.0%,
respectively), while nerve symptoms were more specific
(sensitivity 44.8%; specificity 75.0%). Combining nerve
symptoms and either pain or growth did not improve di-
agnostic accuracy compared to evaluation of nerve symp-
toms alone. Of note, having any two of three symptoms was
more specific and slightly more sensitive than having any
one particular symptom. Having all three symptoms was
insensitive and only moderately specific and therefore not
diagnostically useful (Table 2).
3.2.MRI Findings. Fifty-nine lesions had PET/CT images, of
which 37 had MRI images available for review. Tumor depth
below the fascia was highly sensitive for malignancy (100%)
with 100% NPV, but not specific (20.7%). Increasing tumor
size was predictive of malignancy as a continuous variable in
regression analysis; however, the cutoff of 5 cm (based on the
AJCC system) was neither sensitive nor specific. An ROC
curve was also constructed for tumor size, but with AUC
0.687 (CI 0.539–0.835), there was no clear threshold for
diagnosing malignancy.
Between the two musculoskeletal radiologists reviewing
MRI studies, interobserver agreement was good (kappa
0.608, 95% CI 0.409–0.807) for necrosis by quartiles (none,
0–25%, 25–50%, etc.). Agreement was very good for no
necrosis versus any necrosis (kappa 0.937, 95% CI: 0.816–
1.000) and necrosis less than versus greater than 25% (kappa
0.852, 95% CI: 0.655–1.000). For diagnosing MPNST, any
necrosis seen on MRI was sensitive (87.5%) and fairly







Figure 1: Example of a malignant peripheral nerve sheath tumor in the adductor musculature of the left thigh visualized using (a) magnetic
resonance imaging (MRI) and (b) positron emission tomography (PET) studies. &e hypointense areas marked with the asterisk represent
necrosis within the tumor.
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volume was less sensitive (75.0%) but more specific (95.2%),
with PPV 92.3%.
3.3. PET Findings. &e ROC curves for SUVmax, SUVpeak,
and TLR were noted to have similar AUCs (Table 3). Op-
timal cutoff points were chosen to maximize sensitivity and
specificity based on our patient population. Our cutoff
points for SUVpeak (4.5) and TLR (3.0) were identical to
those in the prior literature, and our cutoff for SUVmax was
similar (5.3 in our data compared to 5.0 in the literature,
with some more conservative cutoffs slightly lower)
[13, 23, 24]. In our dataset, the previously established cutoff
of 5.0 resulted in identical sensitivity but lower specificity
(60% compared to 70%) than our optimal cutoff point of 5.3
(Table 3).
For qualitative assessment, the interobserver agreement
was very good, with kappa 0.896, 95% CI 0.740–1.000. Level
5/5 on the visual scale was considered suggestive of ma-
lignancy. Using these thresholds for diagnosing MPNST,
PET measures were comparable to one another, with
generally good predictive value. Of these, SUVpeak > 4.5 had
the highest sensitivity and NPV and was therefore selected
for testing in combination with MRI necrosis. Positive
findings on either MRI (any necrosis) or PET
(SUVpeak > 4.5) were highly sensitive (95.5%), while posi-
tive findings on both MRI and PET were highly specific
(93.9%).
Logistic regression analysis supported the value of ne-
crosis and PETmeasures for diagnosing MPNST. Depth was
found to have 100% sensitivity, with all malignancies oc-
curring deep to the fascia in our population; therefore, only
27 deep tumors were included for the development of
prediction models. In order to prevent multicollinearity
between similar measures, SUVpeak> 4.5 was selected to
represent PET measures, and necrosis >25% of the tumor
volume was chosen to represent MRI findings. &us, tumor
size, necrosis >25%, and SUVpeak were selected as the rel-
evant variables; when these were entered for deep tumors,
necrosis was the only significant predictor (p � 0.033,
Nagelkerke R2 � 0.622).
3.4. Combined Diagnostic Algorithm. Clinical findings were
not included in the algorithm as they could not reliably rule
out malignancy in our population (NPV 62.3–69.2%).
SUVpeak was included because it had the highest sensitivity
and NPV of the semiquantitative PETparameters; however,
the visual scale was almost identical, and the other PET
measures were not significantly different, so these could be
substituted for SUVpeak with minimal effect.
Tumors were first differentiated by depth relative to the
fascia, which was notable for 100% NPV in our analysis.
While tumor depth may be verified on MRI (as in our
methods), in most cases, it can be easily determined by
physical examination prior to advanced imaging. We
therefore suggest that patients appearing to have deep tu-
mors on physical examination be evaluated with MRI and
PET and that they undergo biopsy in the presence of con-
cerning features on either of these studies. Tumors that are
histologically confirmed to be malignant should be managed
with surgery and neoadjuvant/adjuvant chemotherapy/
radiation according to standard protocols. Unfortunately,
biopsy itself is imperfect due to sampling error [25]. For
tumors that are likely malignant based on imaging but do
not contain evidence of MPNST on initial biopsy, rebiopsy
or wide excision may be indicated; in contrast, observation
may be acceptable for tumors that appear less concerning
(Figure 2). Of note, this algorithm is based solely on our
patient population and will therefore require further
validation.
4. Discussion
&e aim of our study was to report the diagnostic value of
tumor size and depth, MRI features, PET measures, and
clinical findings to distinguish between benign and malig-
nant PNST. In sum, PET measures and necrosis on MRI
were the most predictive of malignancy and can be com-
bined to direct workup and treatment in this challenging
clinical situation. &is algorithm has been adopted at our
institution and will require validation with long-term
follow-up from multiple centers.
Table 1: Descriptive statistics and potential predictors of malig-
nancy for the 70 peripheral nerve sheath tumors in our study
population of 41 NF1 patients. &ese included patient character-
istics (age and gender), PET findings (SUVmax, SUVpeak, and TLR),
MRI findings (size, depth relative to the fascia, and necrosis) and
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Our study had several limitations. It is a retrospective
analysis with a relatively small sample size due to the rarity of
NF1 and MPNST. Most importantly, PET/CT, MRI, and
clinical findings were not available for all patients; however,
these missing data did not correlate with year, age, or
malignancy characteristics. In addition, PET/CT studies
were performed on different scanners at our institution,
potentially resulting in a small amount of measurement
variability that was likely not clinically relevant. Lastly, our
algorithm was developed based on a limited patient pop-
ulation at a single institution, so external validation will be
needed.
4.1. Clinical Findings. Traditional teaching states that most
plexiform neurofibromas are asymptomatic, unless trau-
matized or compressed, while MPNSTs are usually
associated with significant pain [8], but we are unaware of
any evidence supporting this. In our patient population, pain
and growth were more sensitive and nerve symptoms were
Table 3: Areas under the curve (AUC) and associated confidence
intervals (CI) from receiver operating characteristic curves for
SUVmax, SUVpeak, and tumor-to-liver ratio (TLR). Using these
present data, cutoff points were selected to optimize sensitivity and
specificity. Our cutoff point for SUVmax differed slightly from that
established in the previous literature, so the sensitivity and spec-
ificity of the previous cutoff point were calculated using the present
data.
AUC CI Cutoff Sensitivity Specificity
SUVmax 0.85 0.73–0.96 5.3 91.2 70.0
SUVpeak 0.83 0.71–0.96 4.5 91.7 65.0
TLR 0.84 0.71–0.97 3.0 91.3 68.4
Table 2: Sensitivity, specificity, positive predictive values, and negative predictive values, along with their associated confidence intervals, for
potential predictors of malignancy. &ese included tumor characteristics (depth relative to the fascia, and size> 5 cm in diameter), MRI
findings (any necrosis, or necrosis >25% by volume), PET findings (SUVmax> 5, SUV peak> 4.5, and TLR> 3), and clinical findings (pain,
enlarging, and nerve symptoms). Combinations of imaging findings (SUVpeak> or< 4.5 on PET and any or >25% necrosis on MRI) and
clinical findings (1 of 3, 2 of 3, or 3 of 3 symptoms) are also included.
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more specific for diagnosing MPNST. However, either in
isolation or combination with one another, clinical findings
were not as predictive as imaging.
4.2. MRI Findings. In the AJCC staging system, sarcomas
greater than 5 cm in diameter are considered at higher risk
for local progression and metastasis. &is is generally ac-
cepted and well supported in the MPNST literature. Of note,
the most recent AJCC Cancer Staging Manual removed
depth of tumor notation from the guidelines; however,
assessment of tumor depth still remains prominent in the
literature [26]. &is is generally accepted and well supported
in the MPNST literature. Kar et al. [27] found that 92% of
malignant tumors were >5 cm and deep to the fascia, while
Hwang et al. [28] reported that 57% of malignant tumors
were >5 cm and 88% were deep to the fascia. We found that
increasing tumor size was predictive of malignancy as a
continuous variable in the regression analysis, but the 5 cm
AJCC cutoff was neither sensitive nor specific. In addition,
ROC analysis did not identify a clear size above which tu-
mors were more likely to be malignant, which limits the
clinical utility of this variable in diagnosing MPNST. All of
our malignant tumors were deep to the fascia, resulting in
sensitivity and NPV of approximately 100%. Our patient
population did not include any superficial MPNSTs. Con-
sistent with this, prior literature suggests that cutaneous
neurofibromas do not have malignant potential, and
subcutaneous neurofibromas are often symptomatic but
very rarely malignant [11, 29]. &erefore, our recommen-
dation would be to observe subcutaneous neurofibromas
and consider excision if they are growing or symptomatic. In
our data, tumor depth had poor specificity for malignancy
(21%), consistent with prior studies [30].
Necrosis, which often results from rapid tumor growth,
generally indicates aggressive behavior in sarcomas. &e
French or FNCLCC system utilizes histologic necrosis, along
with differentiation and mitoses, to define tumor grade
[31, 32]. MRI findings of necrosis have also been associated
with MPNST [12]. Consistent with this, necrosis visualized
on MRI was highly predictive of malignancy in our pop-
ulation. Necrosis greater than 25% was the most specific test
for malignancy in our study (specificity 95.2%; sensitivity
75.0%), while any necrosis was less specific but sensitive
(specificity 76.1%; sensitivity 87.5%). In addition, necrosis
was significant in several iterations of the regression model.
&us, necrosis on MRI may be an indication for biopsy;
furthermore, if histologic necrosis is noted in an otherwise
nondiagnostic tissue specimen, rebiopsy or wide excision of
the tumor should be strongly considered.
4.3.PETFindings. Several semiquantitativemeasures of PET
images have been evaluated and compared for the diagnosis
of MPNST. A review by Treglia et al. found FDG-PET/CT to
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Figure 2: Suggested algorithm for the evaluation and management of PNST concerning for malignancy in patients with NF1. It should be
noted that all predictive values are based solely on our patient population (for confidence intervals, please refer to Table 2) and the algorithm
therefore requires further validation.
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malignant change in NF1 tumors [24]. SUVmax has been
widely used, and most studies report thresholds of <2.5 for
benign and >3.5 for malignant lesions; however, the range of
2.5–3.5 remains indeterminate [24, 33]. Salamon et al. [34]
found SUVmax threshold of >3.5 was sensitive but produced
a relatively high rate of false positives, while TLR was more
specific with a threshold> 2.6. SUVpeak has also been
studied, with benign tumors ranging from 0.72–3.04 and
malignant tumors from 2.41–23.38 [23]. Our analysis
resulted in optimal cutoff values that were comparable to
those in the prior literature for these parameters (Table 3). In
contrast to other studies, we found similar predictive
properties among the quantitative PET measures, with no
advantage of TLR over SUVpeak and SUVmax (Table 2).
Furthermore, a recent study combined PET/MRI and found
similar results, with the benefits of less radiation and su-
perior imaging than combined PET/CT. &is may be an-
other possible modality for the future [35].
Qualitative interpretation of PET imaging has also been
studied in the context of PNST. In a study by Fischer et al.,
lesions with increased uptake were identified and rated on a
five-point visual scale.&ey concluded that PET imaging can
predict growth of PNST but did not examine the relationship
between growth and malignancy [19]. Chirindel et al. also
performed a qualitative analysis of PET studies in which
lesions were visually assessed and dichotomized as either
suspected malignant or benign. On early images (performed
at 1 hour after FDG administration) the sensitivity, speci-
ficity, PPV, and NPV were 91%, 84%, 67%, and 96%, re-
spectively, which are comparable to our findings (94%, 71%,
70%, and 94%, respectively) [18]. &ese results suggest that
qualitative PET measures may be as accurate as semi-
quantitative measures in diagnosing MPNST.
5. Conclusion
Our results confirmed that larger tumors are more likely to
be malignant, although we found no clinically relevant size
threshold, and that MPNSTs superficial to the fascia are
extremely rare. Metabolic measurements were relatively
accurate and comparable to one another diagnostically.
Clinical symptoms may also be helpful, although the limi-
tations of their predictive properties should be understood
and taken into consideration. Finally, necrosis may be a
valuable and thus far underutilized predictor of malignancy.
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